Masimo study finds less than 1% bias and no skin tone discrepancies in neonatal pulse oximetry accuracy. NeoPODS data shows reliable SpO2 readings with minimal hypoxemia cases across diverse newborn ...
NEUCHATEL, Switzerland-- (BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse ...
Pulse oximetry is used to guide critical clinical decisions in neonatology. We used a vital signs simulator to compare performance of two pulse oximetry systems in conditions not tested in ...
These promising results-from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population-add to previously published evidence of its strong ...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced Dual SET ® Pulse Oximetry for Root ®, a highly versatile patient monitoring and connectivity hub. The first application ...
CHICAGO & IRVINE, Calif.--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) and Masimo (Nasdaq: MASI) today announced a joint agreement to integrate Masimo Signal Extraction Technology® (SET®) pulse ...
About a year after beginning its full market launch, Masimo’s W1 smartwatch can now be used as a medical device in the U.S. The wearable device has earned FDA clearance for its medical applications, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results